Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.

Trial Profile

Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Vincristine (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Haematological malignancies; Hepatic tumours; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 28 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top